Clinical Trials · NCT07642635
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- Phase
- Phase 1/Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 30
- Start date
- Sep 2026
- Locations
- 1 site, United States
- Primary endpoint
- Muscle Volume Index (MVI)